AFTER TAKING AN ANTI-TNF
Are you familiar with the term anti-TNFs? Anti-TNFs are among a class of rheumatoid arthritis (RA) treatments called biologics, and the name stands for anti-tumor necrosis factor. They're usually the first biologic to be given upon diagnosis with RA.* Many people have success with anti-TNFs. But if these treatments stop working well, some may decide to make a change after talking with their doctor. Sometimes those people will try another anti-TNF treatment; however, many have worked with their doctor to choose a different type of treatment, like B-cell therapy.
CONSIDER AN RA TREATMENT THAT WORKS DIFFERENTLY
Unlike anti-TNFs, B-cell therapy targets a type of white blood cell called a B-cell, which is believed to play a role in the symptoms and joint damage of RA. Currently, Rituxan® (rituximab) in combination with methotrexate is the only B-cell therapy approved to treat RA.
Before receiving Rituxan, tell your healthcare provider if you:
- have had a severe reaction to Rituxan or a rituximab product
- have a history of other medical conditions
- have had a severe infection, currently have an infection, or have a weakened immune system
- have had a recent vaccination or are scheduled to receive vaccinations. You should not get certain vaccines before or during treatment with Rituxan
- have any other medical conditions
- are pregnant or planning to become pregnant. Talk to your healthcare provider about the risks to your unborn baby if you receive Rituxan during pregnancy. Talk to your healthcare provider about effective birth control
- are breastfeeding or plan to breastfeed. It is not known if Rituxan passes into your breast milk
- are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements
Please see the Important Side Effect Information page and the Rituxan Prescribing Information and Medication Guide for additional Important Side Effect Information, including Most Serious Side Effects.
*Common anti-TNF treatments are Cimzia® (certolizumab pegol), Enbrel® (etanercept), Humira® (adalimumab), Remicade® (infliximab), and Simponi® (golimumab). All trademarks are the property of their respective owners. All treatments are prescription only.